Report Overview

The EU Oral Anti-Diabetes Drugs market was estimated to be more than $XX Billions in 2019 and is expected to reach $XX Billions by 2028, exhibiting a CAGR of XX% during the forecast period

Diabetes is a chronic disease that occurs when the body cannot effectively use the produced insulin or the pancreas does not produce sufficient insulin. There are about 60 million people with diabetes in the EU, or about 10.3% of men and 9.6% of women aged 25 years and over. The prevalence of diabetes is increasing among all ages in the European Region, mostly due to increases in overweight and obesity, unhealthy diet, and physical inactivity. Among the diabetes drugs in the EU, oral anti-diabetic and insulin drugs occupy a significant market share. The German generics market is vast, and the market for oral anti-diabetes drugs is expected to increase during the period 2019-2028. However, pricing is a major issue in Germany, and many companies have backed up with their plan to launch insulin in the country. In France, the oral DPP-4 drugs dominate the market, followed by GLP-1 and Insulin. Currently, about 10% of all diabetes cases are Type-1 and the remaining are of Type-2. Thus, the rise in the prevalence of type-2 diabetes worldwide is likely to create a vast demand for diabetes drugs



 

Market Growth Drivers

The EU Oral Anti-Diabetes Drugs Market is estimated to be growing because of the rise in the Type 2 diabetes population. The significant growth in the market can be attributed to factors such as the rising prevalence of diabetes and the increasing number of programs initiated by various health organizations related to health awareness. Also, ongoing research on diabetic treatment and high market potential are expected to create opportunities in the oral anti-diabetes market in the near future